Altimmune Inc (ALT)

Mar 17, 2025, 3:21 PM EDT - 5 weeks ago

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Mar 13, 2025, 5:26 PM EDT - 5 weeks ago

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Mar 6, 2025, 7:30 AM EST - 6 weeks ago

Altimmune to Host Virtual R&D Day on March 13, 2025

Mar 3, 2025, 7:30 AM EST - 7 weeks ago

Altimmune to Participate in the Leerink Global Healthcare Conference

Feb 28, 2025, 2:15 PM EST - 7 weeks ago

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Feb 27, 2025, 2:24 PM EST - 7 weeks ago

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 7 weeks ago

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 25, 2025, 7:30 AM EST - 2 months ago

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Feb 20, 2025, 7:30 AM EST - 2 months ago

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 18, 2025, 5:26 AM EST - 2 months ago

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Feb 14, 2025, 6:32 PM EST - 2 months ago

Final Trade: WST, BTC, GLD, ALT

GLD BTC WST

Jan 29, 2025, 7:30 AM EST - 3 months ago

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 11:42 AM EST - 4 months ago

Altimmune Could Find A Partner For Its Phase 3 Exercise

Dec 19, 2024, 7:30 AM EST - 4 months ago

Altimmune Added to Nasdaq Biotechnology Index

Dec 16, 2024, 3:14 AM EST - 4 months ago

Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 3, 2024, 6:04 PM EST - 5 months ago

Altimmune CEO on what's next for its experimental obesity drug

Nov 26, 2024, 7:30 AM EST - 5 months ago

Altimmune to Participate at Two Upcoming Investor Conferences

Nov 19, 2024, 6:29 PM EST - 5 months ago

Final Trade: C, NVDA, XLF, ALT

NVDA XLF C

Nov 15, 2024, 11:00 AM EST - 5 months ago

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Nov 13, 2024, 3:43 PM EST - 5 months ago

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge

Nov 13, 2024, 12:38 PM EST - 5 months ago

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 12, 2024, 10:00 AM EST - 5 months ago

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:30 AM EST - 5 months ago

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 11, 2024, 7:30 AM EST - 5 months ago

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Nov 7, 2024, 7:30 AM EST - 5 months ago

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Nov 4, 2024, 7:30 AM EST - 6 months ago

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Oct 15, 2024, 8:00 AM EDT - 6 months ago

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

Oct 2, 2024, 2:48 PM EDT - 7 months ago

Consider Buying Potential Takeover Target Altimmune

Oct 1, 2024, 7:30 AM EDT - 7 months ago

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Sep 30, 2024, 7:30 AM EDT - 7 months ago

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sep 21, 2024, 5:21 AM EDT - 7 months ago

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 10, 2024, 1:09 PM EDT - 8 months ago

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Sep 10, 2024, 7:45 AM EDT - 8 months ago

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Sep 3, 2024, 7:30 AM EDT - 8 months ago

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Aug 27, 2024, 11:26 AM EDT - 8 months ago

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 10, 2024, 9:03 AM EDT - 9 months ago

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 9 months ago

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Aug 1, 2024, 7:30 AM EDT - 9 months ago

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 25, 2024, 7:30 AM EDT - 9 months ago

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Jul 3, 2024, 9:55 AM EDT - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Jul 2, 2024, 7:30 AM EDT - 10 months ago

Altimmune to Participate at Leerink Partners Therapeutics Forum